Share-Based Payment (Tables)
|
12 Months Ended |
Jun. 30, 2026 |
|---|
| Share-Based Payment [Abstract] |
|
| Schedule of Share-Based Payment Transactions Recognised as an Expense |
Total costs arising from share-based payment transactions recognised as an expense during the year were as follows: | | | 30 June
2026
$ | | | 30 June
2025
$ | | | 30 June
2024
$ | | | Issue of RSUs to Directors and management (i) | | | 61,332,980 | | | | 27,044,194 | | | | 608,156 | | | Issue of RSUs to consultant (ii) | | | 290,223 | | | | | | | | | | | Issue of RSU’s to suppliers – Chris Gale | | | - | | | | 80,700 | | | | - | | | Issue of shares to suppliers – Bellatrix Corporate Pty Ltd | | | - | | | | 807,000 | | | | - | | | Issue of shares to director – Tony Sage | | | - | | | | 1,200,000 | | | | - | | | Issue of shares to suppliers – Alberta Inc (iii) | | | 4,371,000 | | | | 955,000 | | | | - | | | Issue of shares to suppliers - Skylong Asset Limited | | | - | | | | 480,000 | | | | - | | | | | | 65,994,203 | | | | 30,566,894 | | | | 608,156 | | | | (i) | RSUs to Directors and Management | On 1 November 2025, the Company issued 6,230,000 restricted stock units (RSU’s) and 7,470,000 premium vested options (PVO’s) of which 5,110,000 RSU’s and 6,030,000 PVO’s were issued to directors and KMP of the Company.
|
| Schedule of Trading Price on the Date of Issue with the Overall Cost to be Spread Over the Vesting Period |
The RSU’s vest equally over a three year term and have been valued based on the trading price on the date of issue with the overall cost spread over the vesting period. An amount of $36,520,540 has been booked in the accounts at 30 June 2026. | | | Number of
RSU’s | | | Grant date | | Fair value
at grant
date $
per right | | | Vesting
Date | | Executives | | | 1,831,667 | | | 1 November 2025 | | $ | 12.94 | | | 1 November 2026 | | Executives | | | 1,831,667 | | | 1 November 2025 | | $ | 12.94 | | | 1 November 2027 | | Executives | | | 1,831,667 | | | 1 November 2025 | | $ | 12.94 | | | 1 November 2028 | | Advisors | | | 315,000 | | | 1 November 2025 | | $ | 12.94 | | | 1 November 2026 | | Non-Executive Directors | | | 420,000 | | | 1 November 2025 | | $ | 12.94 | | | 1 November 2026 | | | | Number of
PVO’s | | | Grant date | | Fair value
at grant
date $
per right | | | Share price hurdle | | | Vesting
Date | | Executives, Advisors and Non-Executive Directors | | | 2,490,000 | | | 1 November 2025 | | $ | 8.12 | | | US$ | 16.25 | | | 31 October 2026 | | Executives, Advisors and Non-Executive Directors | | | 2,490,000 | | | 1 November 2025 | | $ | 8.57 | | | US$ | 20.31 | | | 31 October 2027 | | Executives, Advisors and Non-Executive Directors | | | 2,490,000 | | | 1 November 2025 | | $ | 8.80 | | | US$ | 25.39 | | | 31 October 2028 |
|
| Schedule of Following Key Assumptions Were Used in Monte Carlo Simulation Model in Determining the Grant Date Fair Value of PVOs |
The following key assumptions were used in the Monte Carlo Simulation model in determining the grant-date fair value of the PVOs: | Tranche | | | 1 | | | | 2 | | | | 3 | | | Vesting date | | | 31 October 2026 | | | | 31 October 2027 | | | | 31 October 2028 | | | Share price at grant date | | US$ | 12.88 | | | US$ | 12.88 | | | US$ | 12.88 | | | Exercise price | | US$ | 12.88 | | | US$ | 12.88 | | | US$ | 12.88 | | | Expected volatility | | | 118.6 | % | | | 102 | % | | | 97.5 | % | | Risk-free interest rate | | | 3.72 | % | | | 3.72 | % | | | 3.72 | % | | Expected life | | | 5 years | | | | 5 years | | | | 5 year | | | Expected dividend yield | | | Nil | | | | Nil | | | | Nil | | The following key assumptions were used in the Monte Carlo Simulation model in determining the grant-date fair value of the PVOs: | Tranche | | | 1 | | | | 2 | | | | 3 | | | Vesting date | | | 31 October 2026 | | | | 31 October 2027 | | | | 31 October 2028 | | | Share price at grant date | | | US$9.27 | | | | US$9.27 | | | | US$9.27 | | | Exercise price | | | US$12.88 | | | | US$12.88 | | | | US$12.88 | | | Expected volatility | | | 90 | % | | | 90 | % | | | 90 | % | | Risk-free interest rate | | | 3.885 | % | | | 3.885 | % | | | 3.885 | % | | Expected life | | | 4.54 years | | | | 4.54 years | | | | 4.54 year | | | Expected dividend yield | | | Nil | | | | Nil | | | | Nil | |
|
| Schedule of Expected Dividend Policy and Historical Dividend Yield |
The expected life reflects the midpoint between the vesting period and contractual life and the expected dividend yield was based on the Company’s expected dividend policy and historical dividend yield. | | | Number of PVOs | | | Weighted average exercise price | | | Outstanding at 1 July 2025 | | Nil | | | | | | Granted during the year | | | 7,470,000 | | | US$ | 12.88 | | | Exercised during the year | | | Nil | | | | | | | Forfeited/lapsed during the year | | | Nil | | | | | | | Outstanding at 30 June 2026 | | | 7,470,000 | | | US$ | 12.88 | | | Exercisable at 30 June 2026 | | | - | | | | | |
|
| Schedule of Valued Based on the Trading Price Date of Issue with Overall Cost Spread Over the Vesting Period |
The RSU’s vest equally over a three year term and have been valued based on the trading price on the date of issue with the overall cost spread over the vesting period. An amount of $169,700 has been booked in the accounts at 30 June 2026. | | | Number of
RSU’s | | | Grant date | | Fair value
at grant
date $
per right | | | Vesting
Date | | Consultant | | | 50,000 | | | 16 April 2026 | | $ | 9.27 | | | 30 April 2027 | | Consultant | | | 50,000 | | | 16 April 2026 | | $ | 9.27 | | | 30 April 2028 | | Consultant | | | 50,000 | | | 16 April 2026 | | $ | 9.27 | | | 30 April 2029 | The PVO’s have an exercise price of $12.88, vest equally over a three year term, expire on 30 October 2035 and have been valued using the Monte Carlos Simulation (MCS) model taking into account the terms and conditions upon which the PVO’s were granted with the overall cost spread over the vesting period. An amount of $120,523 has been booked in the accounts at 30 June 2026. | | | Number of
PVO’s | | | Grant date | | Fair value
at grant
date $
per right | | | Vesting
Date | | Consultant | | | 60,000 | | | 16 April 2026 | | $ | 2.67 | | | 31 October 2026 | | Consultant | | | 60,000 | | | 16 April 2026 | | $ | 4.42 | | | 31 October 2027 | | Consultant | | | 60,000 | | | 16 April 2026 | | $ | 5.06 | | | 31 October 2028 | | | | Number of
Shares | | | Grant date | | Fair value
at grant
date $
per right | | | Vesting
Date | | Alberta Inc | | | 100,000 | | | 8 October 2025 | | $ | 11.79 | | | 30 June 2026 | | Alberta Inc | | | 400,000 | | | 3 October 2025 | | $ | 7.98 | | | 2 February 2026 |
|